New guidelines on eosinophilic esophagitis management were recently developed with the aim of informing treatment decisions among pediatric and adult allergists and gastroenterologists.
Dupilumab was associated with clinical and anatomic improvements in patients with eosinophilic esophagitis, according to results from a pivotal phase 3 study.
Risk factors for bronchiectasis in patients with AERD include older age as well as the presence of allergic bronchopulmonary aspergillosis, aspiration, mycobacterial infection, and pneumonia.
The FDA has expanded the approval of dupilumab to include patients aged 6 to 11 years with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
CSJ117, formulated as an engineered powder in hard capsules for delivery to the lungs via dry powder inhaler, may be the first inhaled anti-thymic stromal lymphopoietin treatment for adults with mild asthma.
Eyevance announced the launch of Zerviate™ (cetirizine ophthalmic solution) 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in patients 2 years of age and older.
The American College of Allergy, Asthma and Immunology (ACAAI) has issued a statement regarding the use of corticosteroids for patients with allergies and asthma.
Possible device malfunctions and use errors may delay or prevent treatment with EpiPen (epinephrine 0.3mg) and EpiPen Jr (epinephrine 0.15mg) autoinjectors, as well as the authorized generic versions.
Aimmune announced that the first US patients are being treated with Palforzia™ (Peanut [Arachis hypogaea] Allergen Powder-dnfp), an oral immunotherapy for peanut allergy.
